Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid tumors after chronic lymphocytic leukemia.

M Hisada1, R J Biggar, M H Greene

  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA. mh280i@nih.gov

Blood
|September 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rising incidence of gastric cardia cancer.

Journal of the National Cancer Institute·1999
Same author

Hip and knee implantations among patients with osteoarthritis and risk of cancer: a record-linkage study from Denmark.

International journal of cancer·1999
Same author

Rising incidence of renal cell cancer in the United States.

JAMA·1999
Same author

Lipid-lowering medication and risk of cancer.

Journal of clinical epidemiology·1999
Same author

Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas.

British journal of cancer·1999
Same author

Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study.

British journal of cancer·1999
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Patients with chronic lymphocytic leukemia (CLL) face a higher risk of developing second cancers. This includes Kaposi sarcoma, melanoma, and cancers of the lung, larynx, brain, stomach, and bladder.

Area of Science:

  • Oncology
  • Epidemiology

Background:

  • Chronic lymphocytic leukemia (CLL) is associated with an increased risk of subsequent neoplasms.
  • Understanding these risks is crucial for patient management and surveillance.

Purpose of the Study:

  • To quantify the risk of second cancers in a large cohort of patients diagnosed with CLL.
  • To identify specific cancer types with elevated risks following a CLL diagnosis.

Main Methods:

  • Utilized data from the population-based Surveillance, Epidemiology and End Results (SEER) Program.
  • Analyzed a cohort of 16,367 patients with CLL to calculate observed/expected (O/E) ratios for second cancers.
  • Compared cancer risks between patients who received chemotherapy and those who did not.

Main Results:

Related Experiment Videos

  • An overall increased risk of second cancers was observed (O/E = 1.20).
  • Significant excesses in risk were noted for Kaposi sarcoma (O/E = 5.09), malignant melanoma (O/E = 3.18), lung cancer (O/E = 1.66), and laryngeal cancer (O/E = 1.72).
  • Elevated risks were also found for brain cancer in men (O/E = 1.91) and stomach (O/E = 1.76) and bladder cancers (O/E = 1.52) in women.

Conclusions:

  • Patients with CLL have a statistically significant increased risk of developing various secondary cancers.
  • The findings suggest potential roles for immunologic impairment or other etiologic factors in the development of these subsequent neoplasms.
  • Further research is warranted to elucidate the underlying mechanisms driving these increased cancer risks post-CLL.